MDP:CA Stock

Following a key product update, Raymond James analyst Michael W. Freeman remains bullish on Medexus ... Read More

An FDA approval could send one Canadian-listed stock flying, says Raymond James analysts Michael W. ... Read More

With its second quarter results in the books, Raymond James analyst Michael W. Freeman has raised it... Read More

A new development has been a drag on its share price, but Ventum Capital Markets analyst Stefan Quen... Read More

Its Q4 results are in the books and Raymond James analyst Rahul Sarugaser still thinks there is a li... Read More